Market Overview

UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Covance

Related CVD
Citi Neutral On Lab Sector; Initiates On Quest Diagnostics, Labcorp
KeyBanc Starts Lab Corp Of America At Overweight, But Indebtedness Is A Concern

In a report published Friday, J.P. Morgan reiterated its Overweight rating on Covance (NYSE: CVD), and raised its price target from $68.00 to $70.00.

J.P. Morgan noted, “Given a diversified service offering, increasing geographical footprint, economies of scale, and growing biotechnology and pharmaceutical customer base, which have become increasingly reluctant to outsource work to smaller, less well-funded service organizations, we believe that CVD will continue to command a significant premium valuation to peers.”

Covance closed on Thursday at $67.54.

Latest Ratings for CVD

Nov 2014CitigroupMaintainsNeutral
Nov 2014KeyBancDowngradesBuyHold
Nov 2014Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for CVD
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings


Related Articles (CVD)

View Comments and Join the Discussion!

Partner Center